Federal contract award
75N93018C00023
IGF::OT::IGF - "DEVELOPMENT OF A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS."
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $24.6M |
| Current contract value | $24.6M |
| Potential contract value / ceiling | $40.4M |
| Start date | Sep 20, 2018 |
| Current end date | Jul 22, 2025 |
| Potential end date | Jul 22, 2025 |
| Latest award activity | Aug 6, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 22 of 22 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 6, 2026 | P00021 | $-1.6K | TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. |
| Jul 22, 2025 | P00020 | $-2.7M | EOI::IMPLEMENTING THE PRESIDENT'S DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE::EOI TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Apr 28, 2025 | P00019 | $1.3M | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Mar 8, 2024 | P00018 | $-21.4K | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Sep 6, 2023 | P00017 | $0 | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Jun 30, 2023 | P00016 | $-207.8K | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Apr 28, 2023 | P00015 | $2.1M | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Nov 29, 2022 | P00014 | $0 | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Jun 22, 2022 | P00013 | $0 | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Jun 10, 2022 | P00012 | $0 | EO14042 - TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Dec 1, 2021 | P00011 | $0 | EO14042 - TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Aug 27, 2021 | P00010 | $69.3K | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Jun 10, 2021 | P00009 | $0 | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Jun 7, 2021 | P00008 | $0 | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Dec 18, 2020 | P00007 | $0 | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Aug 31, 2020 | P00006 | $4.4M | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Jul 1, 2020 | P00005 | $659.5K | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Apr 8, 2020 | P00004 | $4.0M | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Jan 29, 2020 | P00003 | $0 | TO DEVELOP A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS. |
| Nov 5, 2019 | P00002 | $0 | IGF OT IGF - "DEVELOPMENT OF A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS." |
| Jul 28, 2019 | P00001 | $2.9M | IGF OT IGF - "DEVELOPMENT OF A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS." |
| Sep 20, 2018 | 0 | $12.1M | IGF::OT::IGF - "DEVELOPMENT OF A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS." |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.